MNG1097
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.533
- ALLOGRAFT_REJECTION+0.482
- IL6_JAK_STAT3_SIGNALING+0.403
- INTERFERON_GAMMA_RESPONSE+0.356
- MYC_TARGETS_V1+0.312
- P53_PATHWAY+0.301
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.298
- OXIDATIVE_PHOSPHORYLATION+0.286
- DNA_REPAIR+0.282
- UV_RESPONSE_UP+0.278
Top 10 suppressed
- UV_RESPONSE_DN-0.399
- G2M_CHECKPOINT-0.396
- PROTEIN_SECRETION-0.391
- E2F_TARGETS-0.305
- HEDGEHOG_SIGNALING-0.290
- ANGIOGENESIS-0.248
- MITOTIC_SPINDLE-0.247
- CHOLESTEROL_HOMEOSTASIS-0.224
- ANDROGEN_RESPONSE-0.221
- ESTROGEN_RESPONSE_EARLY-0.213
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A66H-01A-11R-A29R-07 | — | B | 0.775 |
| 2 | MNG1091 | — | — | 0.762 |
| 3 | C9C70D33-C09B-4F7E-8F12-FDE51817038A | — | — | 0.746 |
| 4 | TCGA-TN-A7HL-01A-11R-A34R-07 | — | — | 0.739 |
| 5 | MNG524 | — | — | 0.735 |
| 6 | MNG1247 | — | — | 0.734 |
| 7 | TCGA-UF-A7JT-01A-11R-A34R-07 | — | — | 0.724 |
| 8 | 21f65654-07a2-4b27-b511-2497fa298d0e | — | — | 0.721 |
| 9 | TCGA-EW-A6SB-01A-12R-A32P-07 | — | E | 0.719 |
| 10 | TCGA-EW-A1IZ-01A-11R-A13Q-07 | — | D | 0.719 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.533 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.482 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.403 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.356 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.312 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.301 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.298 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.286 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.282 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.278 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.276 | Idelalisib | — uncovered |
| COMPLEMENT | 0.223 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.172 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.165 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.164 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.164 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.149 | Inavolisib | — uncovered |
| APOPTOSIS | 0.147 | Idelalisib | — uncovered |
| MYOGENESIS | 0.136 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.113 | Inavolisib | — uncovered |